This dissertation examined the pharmaco-epidemiology of non-CF bronchiectasis and the use of inhaled antibiotics in routine US care using longitudinal administrative claims data from the Merative MarketScan Research Databases, 2015-2024. Its three aims followed the logic of clinical epidemiology. We first characterized the occurrence of bronchiectasis in insured populations, exacerbation rates in a retrospectively assembled cohort, and inhaled antibiotic utilization across the 3 major payer groups in the US; then evaluated the association between inhaled antibiotic initiation and exacerbation incidence among new users using a self-controlled case series design; and lastly examined selected diagnosis-specific adverse events occurring during therapy and around discontinuation.
